Human granulocytic anaplasmosis (HGA) is a newly discovered tick borne disease whose expansion is seriously compromising public health. Our company's advancement as a research service provider assures the world's top pharmaceutical companies that it can assist them with HGA vaccination and therapeutics development for their global markets.
Introduction to Human Granulocytic Anaplasmosis
HGA is a tick-borne rickettsial infection endemic to the Northeastern and Upper Midwestern regions of the US, and is caused primarily by the Anaplasma phagocytophilum agent which affects hosts by infecting neutrophils thereby changing gene expression in hosts to inhibit phagocytosis while allowing bacterial proliferation. Effective treatment remains elusive, with a hitherto largely inexplicable spontaneous recovery remaining the norm for most patients, while a worrying proportion progress to life-threatening complications.
Fig.1 List of countries where the case reports originated. (Dumic I., et al., 2022)
Vaccine Development for Human Granulocytic Anaplasmosis
The increasing prevalence of the illness coupled with the fact that no specific treatment exists has made the need for a HGA vaccine more dire than before. With the aim of preventing infection as well as reducing the severity of the illness, researchers have developed a vaccine targeting the A. phagocytophilum antigen. Some of those methods are:
Recombinant Proteins
Developing proteins that can stimulate a protective immune response without causing disease.
Subunit Vaccines
Utilizing purified components of the bacterium to induce immunity.
Vectored Vaccines
Employing modified viruses to deliver A. phagocytophilum antigens.
Therapeutics Development for Human Granulocytic Anaplasmosis
The diagnostic errors, especially for patients with systemic inflammatory response syndrome, is linked with the language barrier that arises due to concomitant infections with tick-borne pathogens such as Borrelia Burgdorferi and Babesia microti that dilute the accuracy of diagnostic results. The implications of these challenges on patient care and therapeutic strategies, due to the diagnostic ambiguity that HGA presents at its onset, are worrying.
- Doxycycline: Its in vitro effectiveness in clinical settings and practices complements its status as a first line therapeutic whereby the majority of the population show substantial improvement responding to the treatment within a time frame stretching between 24 to 48 hours.
- Rifamycins: This medical dosage, rifampin, is effective in vitro too, although it has been used as an alternative for patients who cannot withstand tetracycline, which is normally useful for pregnant women and children younger than eight years.
- Fluoroquinolones: Evidence as it stands now suggests a possibility that if used as 3rd line for a subset of HGA therapeutics there will be limitations in efficacy.
For more information about our wide range of therapy development services, please follow the link below.
Our Services
Here in our institution, we offer restoring services as a part of HGA research services with the focus on the development of therapies and vaccines among scientists and researchers in development. We possess state of the art equipment and competent scientists. Some of our core capabilities keep on expanding which include:
Disease Models
- C3H/HeN Mouse Infection Models
- SCID Mouse Infection Models
- BALB/c Mouse Infection Models
- Canine Infection Models
- Customized Animal Models
Preclinical Research
- Drug Safety Evaluation
- In Vivo Pharmacokinetics Study
- In Vitro Pharmacokinetics Study
- Activity Testing
- Drug Resistance Evaluation
We have a wide range of research activities extending to in vitro and in vivo practices with a view to testing the safety and efficacy of HGA vaccine and other therapeutic candidates. Our pre clinical investigation capabilities include cellomatic technologies, productive animal models and comprehensive investigations on toxicology. Should you wish to obtain more information and precise estimates for our services, you are more than welcome to contact us.
Reference
- Dumic Igor, et al. "Human granulocytic anaplasmosis—a systematic review of published cases." Microorganisms 10.7 (2022): 1433.
All of our services and products are intended for preclinical research use
only and cannot be used to diagnose, treat or manage patients.
